Ferric Carboxymaltose in Heart Failure With Iron Deficiency: FAIR-HF2
ABSTRACT:
Study at a glance
- Publication type: Multicentre randomized clinical trial
- What it examined: FAIR-HF2 evaluated the efficacy and safety of intravenous ferric carboxymaltose in people with heart failure, left ventricular ejection fraction of 45% or less and iron deficiency.
- Key point: The trial enrolled 1,105 participants at 70 sites in six European countries. Its prespecified outcomes included cardiovascular death or first heart failure hospitalisation and total heart failure hospitalisations.
Why it matters
Large trials give important evidence, but interpretation depends on the full outcome results, adverse events and the match between trial eligibility and an individual patient.
Source
Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. JAMA. 2025. PMID: 40159390. View the PubMed record.
This educational summary is based on the cited publication and is not medical advice. Clinical decisions should be made with an appropriately qualified healthcare professional.
